Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Anna Z. Wec, Andrew S. Herbert, Charles D. Murin, Elisabeth K. Nyakatura, Dafna M. Abelson, J. Maximilian Fels, Shihua He, Rebekah M. James, Marc Antoine de La Vega, Wenjun Zhu, Russell R. Bakken, Eileen Goodwin, Hannah L. Turner, Rohit Jangra, Larry Zeitlin, Xiangguo Qiu, Jonathan R. Lai, Laura M. Walker, Andrew B. Ward, John M. DyeKartik Chandran, Zachary A. Bornholdt

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GPCL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.

Original languageEnglish (US)
Pages (from-to)878-890.e15
JournalCell
Volume169
Issue number5
DOIs
StatePublished - May 18 2017

Fingerprint

Ebolavirus
Glycoproteins
Ebola Hemorrhagic Fever
Fusion reactions
Antibodies
Viruses
Virus Internalization
Endosomes
Protein Subunits
Machinery
Antiviral Agents
Epitopes
Vaccines
Monoclonal Antibodies
Membranes

Keywords

  • 15878
  • Ebola virus
  • ebolavirus
  • EBOV
  • ferret
  • human broadly neutralizing antibodies
  • infection
  • mouse
  • neutralization
  • protection

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wec, A. Z., Herbert, A. S., Murin, C. D., Nyakatura, E. K., Abelson, D. M., Fels, J. M., ... Bornholdt, Z. A. (2017). Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 169(5), 878-890.e15. https://doi.org/10.1016/j.cell.2017.04.037

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. / Wec, Anna Z.; Herbert, Andrew S.; Murin, Charles D.; Nyakatura, Elisabeth K.; Abelson, Dafna M.; Fels, J. Maximilian; He, Shihua; James, Rebekah M.; de La Vega, Marc Antoine; Zhu, Wenjun; Bakken, Russell R.; Goodwin, Eileen; Turner, Hannah L.; Jangra, Rohit; Zeitlin, Larry; Qiu, Xiangguo; Lai, Jonathan R.; Walker, Laura M.; Ward, Andrew B.; Dye, John M.; Chandran, Kartik; Bornholdt, Zachary A.

In: Cell, Vol. 169, No. 5, 18.05.2017, p. 878-890.e15.

Research output: Contribution to journalArticle

Wec, AZ, Herbert, AS, Murin, CD, Nyakatura, EK, Abelson, DM, Fels, JM, He, S, James, RM, de La Vega, MA, Zhu, W, Bakken, RR, Goodwin, E, Turner, HL, Jangra, R, Zeitlin, L, Qiu, X, Lai, JR, Walker, LM, Ward, AB, Dye, JM, Chandran, K & Bornholdt, ZA 2017, 'Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses', Cell, vol. 169, no. 5, pp. 878-890.e15. https://doi.org/10.1016/j.cell.2017.04.037
Wec, Anna Z. ; Herbert, Andrew S. ; Murin, Charles D. ; Nyakatura, Elisabeth K. ; Abelson, Dafna M. ; Fels, J. Maximilian ; He, Shihua ; James, Rebekah M. ; de La Vega, Marc Antoine ; Zhu, Wenjun ; Bakken, Russell R. ; Goodwin, Eileen ; Turner, Hannah L. ; Jangra, Rohit ; Zeitlin, Larry ; Qiu, Xiangguo ; Lai, Jonathan R. ; Walker, Laura M. ; Ward, Andrew B. ; Dye, John M. ; Chandran, Kartik ; Bornholdt, Zachary A. / Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. In: Cell. 2017 ; Vol. 169, No. 5. pp. 878-890.e15.
@article{bb34afe1609540a89bcabb2881d5c219,
title = "Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses",
abstract = "Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GPCL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.",
keywords = "15878, Ebola virus, ebolavirus, EBOV, ferret, human broadly neutralizing antibodies, infection, mouse, neutralization, protection",
author = "Wec, {Anna Z.} and Herbert, {Andrew S.} and Murin, {Charles D.} and Nyakatura, {Elisabeth K.} and Abelson, {Dafna M.} and Fels, {J. Maximilian} and Shihua He and James, {Rebekah M.} and {de La Vega}, {Marc Antoine} and Wenjun Zhu and Bakken, {Russell R.} and Eileen Goodwin and Turner, {Hannah L.} and Rohit Jangra and Larry Zeitlin and Xiangguo Qiu and Lai, {Jonathan R.} and Walker, {Laura M.} and Ward, {Andrew B.} and Dye, {John M.} and Kartik Chandran and Bornholdt, {Zachary A.}",
year = "2017",
month = "5",
day = "18",
doi = "10.1016/j.cell.2017.04.037",
language = "English (US)",
volume = "169",
pages = "878--890.e15",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

AU - Wec, Anna Z.

AU - Herbert, Andrew S.

AU - Murin, Charles D.

AU - Nyakatura, Elisabeth K.

AU - Abelson, Dafna M.

AU - Fels, J. Maximilian

AU - He, Shihua

AU - James, Rebekah M.

AU - de La Vega, Marc Antoine

AU - Zhu, Wenjun

AU - Bakken, Russell R.

AU - Goodwin, Eileen

AU - Turner, Hannah L.

AU - Jangra, Rohit

AU - Zeitlin, Larry

AU - Qiu, Xiangguo

AU - Lai, Jonathan R.

AU - Walker, Laura M.

AU - Ward, Andrew B.

AU - Dye, John M.

AU - Chandran, Kartik

AU - Bornholdt, Zachary A.

PY - 2017/5/18

Y1 - 2017/5/18

N2 - Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GPCL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.

AB - Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GPCL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.

KW - 15878

KW - Ebola virus

KW - ebolavirus

KW - EBOV

KW - ferret

KW - human broadly neutralizing antibodies

KW - infection

KW - mouse

KW - neutralization

KW - protection

UR - http://www.scopus.com/inward/record.url?scp=85019578866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019578866&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.04.037

DO - 10.1016/j.cell.2017.04.037

M3 - Article

C2 - 28525755

AN - SCOPUS:85019578866

VL - 169

SP - 878-890.e15

JO - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -